Is it worthwhile to conduct a randomized controlled trial of glaucoma screening in the united kingdom?

Journal of Health Services Research and Policy

Volumn 19, Issue 1, 2014, Pages 42-51

  Burr, Jennifer ^a   Hernández, Rodolfo ^b   Ramsay, Craig ^b   Prior, Maria ^b   Campbell, Susan ^c   Azuara Blanco, Augusto ^b   Campbell, Marion ^b   Francis, Jill ^b   Vale, Luke ^d  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Decision analysis; Health policy; Ophthalmology; Public health

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; EYE PHOTOGRAPHY; GLAUCOMA; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; INTRAOCULAR PRESSURE; MIDDLE AGED; OCULOPLETHYSMOGRAPHY; OPTIC NERVE PHOTOGRAPHY; PERIMETRY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SCREENING; UNITED KINGDOM; COST BENEFIT ANALYSIS; COST OF ILLNESS; ECONOMICS; EPIDEMIOLOGY; INCIDENCE; MASS SCREENING; PREVALENCE; PROBABILITY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; COST OF ILLNESS; COST-BENEFIT ANALYSIS; GLAUCOMA; GREAT BRITAIN; HUMANS; INCIDENCE; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84901478275     PISSN: 13558196     EISSN: 17581060     Source Type: Journal    
DOI: 10.1177/1355819613499748     Document Type: Article

References (30)

1. Bunce C, Xing W and Wormald R. Causes of blind and partial sight certifications in England and Wales: April 2007-March 2008. Eye (Lond) 2010; 24: 1692-1699
2. Pascolini D and Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol 2012; 96(5): 614-618
3. Quigley HA and Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90: 262-267
4. Maier P, Funk J, Schwarzer G, et al. Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ 2005; 331: 134
5. Burr J, Mowatt G, Siddiqui MAR, et al. The clinical and cost effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. Health Technol Assess 2007; 11: iii-170
6. Grant W and Burke J. Why do some people go blind from glaucoma. Ophthalmology 1982; 89: 991-998
7. Chen PP. Blindness in patients with treated open-angle glaucoma. Ophthalmology 2003; 110: 726-733
8. Fraser S, Bunce C, Wormald R, et al. Deprivation and late presentation of glaucoma: case-control study. BMJ 2001; 322: 639-643
9. Ng WS, Agarwal PK, Sidiki S, et al. The effect of socioeconomic deprivation on severity of glaucoma at presentation. Br J Ophthalmol 2010; 94: 85-87
10. Sukumar S, Spencer F, Fenerty C, et al. The influence of socioeconomic and clinical factors upon the presenting visual field status of patients with glaucoma. Eye (Lond) 2009; 23: 1038-1044
11. Safer MA, Tharps QJ, Jackson T, et al. Determinants of three stages of delay in seeking care at a medical clinic. Med Care 1979; 17: 11-29
12. Andersen BL and Cacioppo JT. Delay in seeking a cancer diagnosis: delay stages and psychophysiological comparison processes. Br J Soc Psychol 1995; 34(Pt 1): 33-52
13. Evans J, Ziebland S and McPherson A. Minimizing delays in ovarian cancer diagnosis: an expansion of Andersen's Model of 'total patient delay'. Fam Pract 2007; 24: 48-55
14. Hernandez RA, Burr JM and Vale LD. OAG screening project G. Economic evaluation of screening for openangle glaucoma. Int J Technol Assess Health Care 2008; 24: 203-211
15. Flanders WD and Longini IM. Estimating benefits of screening from observational cohort studies. Stat Med 1990; 9: 969-980
16. Hatt S, Wormald R and Burr J. Screening for prevention of optic nerve damage due to chronic open angle glaucoma. Cochrane Database Syst Rev 2006; (4): 006129
17. Burr J, Francis J, Azuara-Blanco A, et al. Developing the intervention and outcome components of a proposed randomised controlled trial (RCT) of a National Screening Programme for Open Angle Glaucoma (OAG), 2008. www.abdn.ac.uk/aura (accessed 1 April 2013).
18. Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ 2008; 337: a1655
19. Campbell SE, Azuara-Blanco A, Campbell MK, et al. Developing the specifications of an open angle glaucoma screening intervention in the United Kingdom: a Delphi approach. BMC Health Serv Res 2012; 12: 447, 6963-12-447
20. Burr JM, Campbell MK, Campbell SE, et al. Glaucoma screening Platform Study group. Developing the clinical components of a complex intervention for a glaucoma screening trial: a mixed methods study. BMC Med Res Methodol 2011; 11: 54
21. Prior M, Burr JM, Ramsay CR, et al. Evidence base for an intervention to maximise uptake of glaucoma testing: a theory-based cross-sectional survey. BMJ Open 2012; 2(2): e000710
22. British Household Panel Survey (BHPS). Institute for Social & Economic Research, University of Essex. http://www.iser.essex.ac.uk/bhps (accessed December 2011).
23. Euroqol Group. EuroQol - a new facility for the measurement of health related quality of life. Health Policy 1990; 16: 199-208
24. Personal social services expenditure and unit costs England, 2009-10. http://www.ic.nhs.uk/webfiles/publications/009_Social_Care/pss0910expfinal/pss0910expfinal_update_070311/Personal_Social_Services_Expenditure_Report%202009_10.pdf (accessed December 2011).
25. Sheeran P. Intention-behavior relations: a conceptual and empirical review. In: Stroebe W and Hewstone M (eds) European review of social psychology. Oxford: John Wiley & Sons Ltd, 2002, pp.1-36
26. Briggs A, Claxton K and Sculpher M. Decision modelling for health economic evaluation. Oxford University Press, 2006
27. Traverso CE, Walt JG, Kelly SP, et al. Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. Br J Ophthalmol 2005; 89: 1245-1249
28. Future sight loss UK 1: Economic impact of partial sight and blindness in the UK adult population. http://www.rnib.org.uk/aboutus/Research/reports/prevention/Pages/fsluk1.aspx (accessed December 2011).
29. Meads C and Hyde C. What is the cost of blindness? Br J Ophthalmol 2003; 87: 1201-1204
30. Cook J, Hislop J, Adewuyi T, et al. Assessing methods to specify the target difference for a randomised controlled trial - DELTA (Difference ELicitation in TriAls) review. Health Technol Assess. In press.